Tilray Brands, Inc. last reported quarterly results on Oct 8, 2026, for Q1 FY2027 (the quarter ended Aug 31, 2026): revenue of $257.1 million (+22.7% year over year) and diluted EPS of -$0.32. It usually reports 32–58 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 7, 2027.
Results for Q2 FY2027, the quarter ending around Nov 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Jan 8, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 32–58 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 8, 2026
38 days after quarter end
|
Q1 FY2027
ended Aug 31, 2026
|
257
+22.7%
|
-43
-13297.8%
|
-0.32
|
|
Jul 28, 2026
58 days after quarter end
|
Q4 FY2026
ended May 31, 2026
|
282
+25.5%
|
-50
+96.1%
|
-0.42
+96.8%
|
|
Apr 1, 2026
32 days after quarter end
|
Q3 FY2026
ended Feb 28, 2026
|
207
+11.3%
|
-27
+96.6%
|
-0.24
+97.2%
|
|
Jan 8, 2026
39 days after quarter end
|
Q2 FY2026
ended Nov 30, 2025
|
218
+3.1%
|
-45
+47.4%
|
-0.41
+58.6%
|
|
Oct 9, 2025
39 days after quarter end
|
Q1 FY2026
ended Aug 31, 2025
|
210
+4.7%
|
-0
+99.2%
|
0.00
+100.0%
|
|
Jul 28, 2025
58 days after quarter end
|
Q4 FY2025
ended May 31, 2025
|
225
|
-1,273
|
-13.02
|
|
Apr 8, 2025
39 days after quarter end
|
Q3 FY2025
ended Feb 28, 2025
|
186
|
-789
|
-8.69
|
|
Jan 10, 2025
41 days after quarter end
|
Q2 FY2025
ended Nov 30, 2024
|
211
|
-85
|
-0.99
|
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- TLRY (Nasdaq)
- Fiscal year ends
- May 31
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1731348
- Former names
- Tilray, Inc. (until Jan 10, 2022)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Source: SEC EDGAR filings. This is company-reported data, not investment advice.